A Prospective Dose Finding Study of Iscador Infusion
Status:
Not yet recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
Prospective, dose-escalating mono-center open label dose-finding study without control group
(3+3 design), including a follow-up on-treatment observation. In this study will be recruited
15 patients with a histologically or cytologically confirmed diagnosis of an advanced
malignant disease during a therapy-free interval.Investigational drug:Iscador®P: fermented
aqueous extract of mistletoe grown on pine tree (Viscum album L. subspecies austriacum
(Wiesb.) Vollmann), licensed for subcutaneous (SC) application in Switzerland, Germany,
Austria, Sweden, and South Korea in dosages up to 20 mg.
The initial dose group of the study is set to 40 mg Iscador®P.